Systems and methods are disclosed for cosmetic augmentation by forming a biocompatible cross-linked polymer having a multi-phase mixture with a time release catalyst; injecting the mixture into a patient as a viscous fluid; after injection, activating the catalyst to cross-link the polymer after a predetermined period after injection into a patient; and augmenting soft tissue with the biocompatible cross-linked polymer.

The present invention relates to coatings comprising polyethylene glycol and at least one polyphenolic polymer. In particular, the polyphenolic polymer could be selected from the group consisting of tyrosine-derived polyarylates, linear polyesteramides, dihydroxybenzoate polymers, and resorcinol-derived polymers. The coating of the present invention may also include a drug, such as an antibiotic. The coatings of the present invention are suitable for use as coatings for medical devices, such as orthopedic pins or stents.

Medical device are provided for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is water-soluble. In further embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has a molecular weight of from 80 to 750 or has more than four hydroxyl groups.

A method and apparatus are disclosed for forming a drug coating layer capable of preventing breakage of elongated drug crystals on a surface of a balloon and maintaining the drug crystals in an appropriate shape in order to act on a living body. The method includes supplying a coating solution which contains the water-insoluble drug, a water-soluble additive, an organic solvent, and water to the surface of the balloon and evaporating the organic solvent and the water to form an additive layer containing the water-soluble additive and a protruding crystal having a tip end protruding from the additive layer, cutting a surplus portion protruding from the additive layer of the protruding crystal from a part surrounded by the additive layer and forming the part surrounded by the additive layer as the elongated body, and removing the cut-out surplus portion from the drug coating layer.

The invention discloses a Zn—Ga series alloy and a preparation method and application thereof, belonging to the technical field of medical alloys. The Zn—Ga series alloy includes Zn and Ga, and Ga accounts for 0-30 wt % but not including 0. The preparation method is to mix Zn and Ga or Zn, Ga and trace elements, then to obtain a Zn—Ga series alloy by coating paint after smelting or sintering. The mechanical properties of the prepared Zn—Ga series alloy meet the requirements of the strength and toughness of medical implant materials, and it can be degraded in vivo. It has the dual characteristics of biological corrosion degradation and suitable corrosion rate to provide long-term effective mechanical support.

Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.

The present invention relates to a coating comprising at least one biodegradable polymer, wherein the polymer comprises at least one or a blend of a poly (ester amide) (PEA) having a chemical formula described by structural formula (II), wherein; R.sub.1 is independently selected from the group consisting of (C.sub.2-C.sub.20)alkylene, (C.sub.2-C.sub.20)alkenylene, —(R.sub.9—CO—O—R.sub.10—O—CO—R.sub.9)—, CH R.sub.11—O—CO—R.sub.12—COOCR.sub.11— and combinations thereof; R.sub.3 and R.sub.4 in a single co-monomer m or p, respectively, are independently selected from the group consisting of hydrogen, (C.sub.1-C.sub.6)alkyl, (C.sub.2-C.sub.6)alkenyl, (C.sub.2-C.sub.6)alkynyl, (C.sub.6-C.sub.10)aryl, (C.sub.1C.sub.6)alkyl, —(CH.sub.2)SH, —(CH.sub.2).sub.2S(CH.sub.3), CH.sub.2OH, —CH(OH)CH.sub.3, —(CH.sub.2).sub.4NH.sub.3+, ˜(CH.sub.2).sub.3NHC(═NH.sub.2+)NH.sub.2, —CH.sub.2COOH, (CH.sub.2)COOH, —CH.sub.2—CO—NH.sub.2—CH.sub.2CH.sub.2—CO—NH.sub.2, —CH.sub.2CH.sub.2COOH, CH.sub.3—CH.sub.2—CH(CH.sub.3)—, formula (a), HO-.sub.P-Ph-CH.sub.2—, (CH.sub.3).sub.2—CH—, Ph- NH—, NH—(CH.sub.2).sub.3—C—, NH—CH═N—CH═C—CH.sub.2—. R.sub.5 or R.sub.6 are independently selected from bicyclic-fragments of 1,4:3,6-dianhydrohexitols or from the group consisting of (C.sub.2-C.sub.20)alkylene, (C.sub.2-C.sub.20)alkenylene, alkyloxy, oligoethyleneglycol with a Mw ranging from 44 Da up to 700 Da, —CH.sub.2—CH—(CH.sub.2OH).sub.2, CH.sub.2CH(OH)CH.sub.2 whereby R.sub.5 and R.sub.6 are non identical. R.sub.7 is hydrogen, (C.sub.6-C.sub.10) aryl, (C.sub.1C.sub.6) alkyl or a protecting group such as benzyl- or a bioactive agent; R.sub.8 is independently (C.sub.1-C.sub.20) alkyl or (C.sub.2-C.sub.20)alkenyl; R.sub.9 or R.sub.10 are independently selected from C.sub.2-C.sub.12 alkylene or C.sub.2-C.sub.12 alkenylene and R.sub.11 or R.sub.12 are independently selected from H, methyl, C.sub.2-C.sub.12 alkylene or C.sub.2-C.sub.12 alkenylene.

##STR00001##

An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a first component having a first substrate and a second component having a second substrate. The second component is positioned within the first component. One of the first and second substrates includes a hemostatic agent and the other of the first and second substrates includes an active pharmaceutical ingredient. Kits, systems and methods are disclosed.

An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate having a hemostatic agent and an active pharmaceutical ingredient selectively positioned on the substrate. Kits, systems and methods are disclosed.

The present invention relates to a filler comprising a hyaluronic acid hydrogel having a lift value in a specific range relative to the unit amount (w/w %) of hyaluronic acid included in a filler, in contrast to the modification degree, and as a result of having said lift value the filler exhibits improved high viscoelasticity flow properties, has the advantages of both monophasic and biphasic hyaluronic acid hydrogel fillers, and thus exhibits good tissue-restoring properties, has low mobility when injected into skin whilst still maintaining the shape thereof for a long time, and has minimized deformation of the hyaluronic acid through the minimization of the use of crosslinkers, and thus the natural form of hyaluronic acid molecules can be maintained, enabling a reduction in the occurrence of immune reactions and side effects, and thus has excellent soft tissue restoration properties, volume expansion properties and wrinkle alleviation properties.